Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 13

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 13
---
 your proxy.                                      |
| ● | by                                                                                                                                       
 duly executing a subsequently dated proxy relating to the same shares of MIRA Common Stock and returning it in the postage-paid envelope 
 provided, which subsequent proxy is received before the prior proxy is exercised at the MIRA Annual Meeting; and/or                      |
| ● | by                                                                                                                                       
 attending the MIRA Annual Meeting and voting such shares of MIRA Common Stock during the MIRA Annual Meeting.                            |

If a stockholder who owns shares of MIRA Common Stock in “street name” has instructed a broker, bank or other nominee to vote its shares of MIRA Common Stock, the stockholder must follow directions received from its broker to change those instructions.

Q: Who is paying for this proxy solicitation?

A:MIRA is responsible for the cost of printing and filing of this proxy statement and the proxy card, including any fees paid to the U.S. Securities and Exchange Commission (“SEC”) in connection with filing the proxy statement, and any amendments and supplements thereto, with the SEC. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of MIRA Common Stock for the forwarding of solicitation materials to the beneficial owners of MIRA Common Stock. MIRA will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. In addition to these proxy materials, MIRA’s directors and employees may also solicit proxies in person, by telephone or by other means of communication.

Questions Relating to the Merger

Q: What is the Merger?

MIRAPHARM Acquisition, Inc., a Delaware corporation and wholly owned subsidiary of MIRA (“Merger Sub”), and SKNY Pharmaceuticals, Inc., a Delaware corporation (“SKNY”), entered into the Agreement and Plan of Merger and Reorganization on June 16, 2025 (the “Merger Agreement”). The Merger Agreement, as it may be further amended from time to time, contains the terms and conditions of the proposed transaction among MIRA, Merger Sub and SKNY. Under the Merger Agreement, Merger Sub will merge with and into SKNY, with SKNY surviving as a wholly owned subsidiary of MIRA (the “Merger”).

At the effective time of the Merger (the “Effective Time”), each outstanding share of common stock of SKNY, $0.0001 par value per share (“SKNY Common Stock